Overview of Magnetic Resonance Spectroscopy Studies in White Matter Diseases Other than Multiple Sclerosis

  • N. De Stefano
  • A. Federico
Part of the Topics in Neuroscience book series (TOPNEURO)


The advent of magnetic resonance (MR) imaging (MRI) has revolutionized the clinical approach to the evaluation of brain white matter (WM) disorders and has contributed significantly to the growth in our understanding of these diseases. The clinical importance of MRI in the management of patients with WM disorders lies in its great sensitivity for detecting brain lesions. However, in these disorders WM lesions can be due to a variety of pathological processes (autoimmune, metabolic, vascular, toxic, hereditary, etc.) and can be associated with many different types of myelin abnormalities (demyelination, hypomyelination, myelin rarefaction, etc.) [1].


Multiple Sclerosis Fabry Disease Magnetic Resonance Spectroscopic Imaging White Matter Disease Metachromatic Leukodystrophy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kolodny EH (1993) Dysmyelinating and demyelinating conditions in infancy. Curr Opin Neurol Neurosurg 6: 379–386PubMedGoogle Scholar
  2. 2.
    Constans JM, Meyerhoff DJ, Norman D et al. (1995) White matter signal changes, H-1 and P-31 magnetic resonance spectroscopic imaging of white matter signal hypeintensity areas in elderly subjects. Neuroradiology 37: 615–623PubMedCrossRefGoogle Scholar
  3. 3.
    Meyer JS, Kawamura J, Terayama Y (1992) White matter lesions in the elderly. J Neurol Sci 110: 1–7PubMedCrossRefGoogle Scholar
  4. 4.
    van der Knaap MS, Valk J, de Neeling N, Nauta JJ (1991) Pattern recognition in magnetic resonance imaging of white matter disorders in children and young adults. Neuroradiology 33: 478–493PubMedCrossRefGoogle Scholar
  5. 5.
    Federico A, De Stefano N (1997) New perspectives in clinical neurology: the promise0 of non-conventional magnetic resonance techniques. Ital J Neurol Sci 18: 319–320PubMedCrossRefGoogle Scholar
  6. 6.
    Arnold DL, Matthews PM (1996) Practical aspects of clinical applications of MRS in the brain. In: Young IR, Charles HC (eds) MR spectroscopy: clinical applications and0 techniques. Martin Dunitz, London, pp 139–159Google Scholar
  7. 7.
    De Stefano N, Federico A, Arnold DL (1997) Proton magnetic resonance spectroscopy in brain white matter disorders. Ital J Neurol Sci 18: 331–339PubMedCrossRefGoogle Scholar
  8. 8.
    De Stefano N, Matthews PM, Antel JP et al (1995) Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38: 901–909PubMedCrossRefGoogle Scholar
  9. 9.
    Koopmans RA, Li DK, Zhu G et al (1993) Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products [letter]. Lancet 341:631–632PubMedCrossRefGoogle Scholar
  10. 10.
    Narayana PA, Doyle TJ, Lai D, Wolinsky JS (1998) Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43: 56–71PubMedCrossRefGoogle Scholar
  11. 11.
    De Stefano N, Matthews PM, Arnold DL (1995) Reversible decreases in AT-acetylaspartate after acute brain injury. Magn Reson Med 34: 721–727PubMedCrossRefGoogle Scholar
  12. 12.
    Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of Nacetyl-aspartate with monoclonal antibodies. Neuroscience 45: 37–45PubMedCrossRefGoogle Scholar
  13. 13.
    Matthews PM, De Stefano N, Narayanan S et al (1998) Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 18: 327–336PubMedCrossRefGoogle Scholar
  14. 14.
    Davies SE, Newcombe J, Williams SR et al (1995) High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 64: 742–748PubMedCrossRefGoogle Scholar
  15. 15.
    Bruhn H, Kruse B, Korenke GC et al (1992) Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders. J Comput Assist Tomogr 16: 335–344PubMedCrossRefGoogle Scholar
  16. 16.
    Johannik K, van Hecke P, Francois B et al (1994) Localized brain proton NMR spectroscopy in young adult phenylketonuria patients. Magn Reson Med 31: 53–57PubMedCrossRefGoogle Scholar
  17. 17.
    Kruse B, Hanefeld F, Christen HJ et al (1993) Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol 241: 68–74PubMedCrossRefGoogle Scholar
  18. 18.
    van der Knaap MS, van der Grond J, Luyten PR et al (1992) 1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders. Ann Neurol 31: 202–211PubMedCrossRefGoogle Scholar
  19. 19.
    De Stefano N, Dotti MT, Mortilla M et al (2000) Evidence of diffuse brain pathology and unspecific genetic characterization in a patient with an atypical form of adultonset Krabbe disease. J Neurol 247: 226–228PubMedCrossRefGoogle Scholar
  20. 20.
    van der Knaap MS, Barth PG, Stroink H et al (1995) Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol 37: 324–334PubMedCrossRefGoogle Scholar
  21. 21.
    van der Knaap MS, Barth PG, Gabreels FJ et al (1997) A new leukoencephalopathy with vanishing white matter. Neurology 48: 845–855PubMedCrossRefGoogle Scholar
  22. 22.
    Austin SJ, Connelly A, Gadian DG et al (1991) Localized 1H NMR spectroscopy in Canavan’s disease: a report of two cases. Magn Reson Med 19: 439–445PubMedCrossRefGoogle Scholar
  23. 23.
    Grodd W, Krageloh-Mann I, Petersen D et al (1990) In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan’s disease) by proton spectroscopy [letter]. Lancet 336: 437–438PubMedCrossRefGoogle Scholar
  24. 24.
    Matthews PM, Andermann F, Silver K et al (1993) Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 43: 2484–2490CrossRefGoogle Scholar
  25. 25.
    Tzika AA, Ball WS Jr, Vigneron DB et al(1993) Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy. Radiology 189: 467–480PubMedGoogle Scholar
  26. 26.
    Kruse B, Barker PB, van Zijl PC et al (1994) Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 36: 595–608PubMedCrossRefGoogle Scholar
  27. 27.
    Hunt AL, Orrison WW, Yeo RA et al (1989) Clinical significance of MRI white matter lesions in the elderly. Neurology 39: 1470–1474PubMedCrossRefGoogle Scholar
  28. 28.
    Schmidt R, Hayn M, Fazekas F et al (1996) Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke 27: 2043–2047PubMedCrossRefGoogle Scholar
  29. 29.
    Hershey LA, Modic MT, Greenough PG, Jaffe DF (1987) Magnetic resonance imaging in vascular dementia. Neurology 37: 29–36PubMedCrossRefGoogle Scholar
  30. 30.
    Liu CK, Miller BL, Cummings JL et al (1992) A quantitative MRI study of vascular dementia. Neurology 42: 138–143PubMedCrossRefGoogle Scholar
  31. 31.
    Wahlund LO (1994) Brain imaging and vascular dementia. Dementia 5: 193–196PubMedGoogle Scholar
  32. 32.
    Hachinski V (1992) Preventable senility: a call for action against the vascular dementias. Lancet 340: 645–648PubMedCrossRefGoogle Scholar
  33. 33.
    Pantoni L, Garcia JH (1995) The significance of cerebral white matter abnormalities 100 years after Binswanger’s report. A review. Stroke 26: 1293–1301PubMedCrossRefGoogle Scholar
  34. 34.
    MacKay S, Meyerhoff DJ, Constans JM et al (1996) Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 53: 167–174PubMedCrossRefGoogle Scholar
  35. 35.
    Ross BD, Bluml S, Cowan R et al (1997) In vivo magnetic resonance spectroscopy of human brain: the biophysical basis of dementia. Biophys Chem 68: 161–172PubMedCrossRefGoogle Scholar
  36. 36.
    Doraiswamy PM, Charles HC, Krishnan KR (1998) Prediction of cognitive decline in early Alzheimer’s disease [letter]. Lancet 352: 1678PubMedCrossRefGoogle Scholar
  37. 37.
    Rai GS, McConnell JR, Waldman A et al (1999) Brain proton spectroscopy in dementia: an aid to clinical diagnosis [letter]. Lancet 353:1063–1064PubMedCrossRefGoogle Scholar
  38. 38.
    Tedeschi G, Bonavita S, Banerjee TK et al (1999) Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 52: 1663–1667PubMedCrossRefGoogle Scholar
  39. 39.
    De Stefano N, Mortilla M, Dotti MT et al (2000) Metabolic changes in brains of patients with CADASIL and their relevance to disability. Neurology 54: S39(Abstract)CrossRefGoogle Scholar
  40. 40.
    Dubeau F, De Stefano N, Zifkin BG et al (2000) Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Ann Neurol 47: 179–185PubMedCrossRefGoogle Scholar
  41. 41.
    Chong WK, Sweeney B, Wilkinson ID et al (1993) Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology 188: 119–124PubMedGoogle Scholar
  42. 42.
    Menon DK, Baudouin CJ, Tomlinson D, Hoyle C (1990) Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging. J Comput Assist Tomogr 14,882–885PubMedCrossRefGoogle Scholar
  43. 43.
    Wilkinson ID, Miller RF, Miszkiel KA et al (1997) Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection. AIDS 11: 289–295PubMedCrossRefGoogle Scholar
  44. 44.
    Tracey I, Carr CA, Guimaraes AR et al (1996) Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: a proton magnetic resonance spectroscopic study [published erratum appears in Neurology 1996 46:1787]. Neurology 46: 783–788PubMedCrossRefGoogle Scholar
  45. 45.
    Husted CA, Goodin DS, Hugg JW et al (1994) Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 3IP and 1H spectroscopic imaging. Ann Neurol 36: 157–165PubMedCrossRefGoogle Scholar
  46. 46.
    De Stefano N, Narayanan S, Matthews PM et al (1999) In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 122: 1933–1939PubMedCrossRefGoogle Scholar
  47. 47.
    Arnold DL, Matthews PM, Francis GS et al (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31: 235–241PubMedCrossRefGoogle Scholar
  48. 48.
    Petroff OA, Graham GD, Blamire AM et al (1992) Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes. Neurology 42: 1349–1354PubMedCrossRefGoogle Scholar
  49. 49.
    De Stefano N, Matthews PM, Ford B et al (1995) Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 45: 1193–1198PubMedCrossRefGoogle Scholar
  50. 50.
    Davie CA, Barker GJ, Webb S et al (1995) Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118:1583–1592PubMedCrossRefGoogle Scholar
  51. 51.
    Fu L, Matthews PM, De Stefano N et al (1998) Imaging axonal damage of normalappearing white matter in multiple sclerosis. Brain 121: 103–113PubMedCrossRefGoogle Scholar
  52. 52.
    De Stefano N, Matthews PM, Fu L et al (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121: 1469–1477PubMedCrossRefGoogle Scholar
  53. 53.
    Davie CA, Silver NC, Barker GJ et al (1999) Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatr 67: 710–715PubMedCrossRefGoogle Scholar
  54. 54.
    Lee MA, Blamire AM, Pendlebury S et al (2000) Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 57: 65–70PubMedCrossRefGoogle Scholar
  55. 55.
    Vion-Dury J, Nicoli F, Salvan AM et al (1995) Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy [letter]. Lancet 345: 60–61PubMedCrossRefGoogle Scholar
  56. 56.
    De Stefano N, Dotti MT, Mortilla M, Federico A (2001) Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain (in press)Google Scholar
  57. 57.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452PubMedCrossRefGoogle Scholar
  58. 58.
    Hanefeld F, Holzbach U, Kruse B et al (1993) Diffuse white matter disease in three children: an encephalopathy with unique features on magnetic resonance imaging and proton magnetic resonance spectroscopy. Neuropediatrics 24: 244–248PubMedCrossRefGoogle Scholar
  59. 59.
    Tedeschi G, Schiffmann R, Barton NW et al (1995) Proton magnetic resonance spectroscopic imaging in childhood ataxia with diffuse central nervous system hypomyelination. Neurology 45:1526–1532PubMedCrossRefGoogle Scholar
  60. 60.
    Bardosi A, Creutzfeldt W, Di Mauro S et al (1987) Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase. A new mitochondrial multisystem disorder. Acta Neuropathol 74: 248–258PubMedCrossRefGoogle Scholar
  61. 61.
    Burgeois M, Goutieres F, Chretien D et al (1992) Deficiency in complex II of the respiratory chain, presenting as a leukodystrophy in two sisters with Leigh syndrome. Brain Dev 14: 404–408PubMedCrossRefGoogle Scholar
  62. 62.
    Leutner C, Layer G, Zierz S et al (1994) Cerebral MR in ophthalmoplegia plus. AJNR Am J Neuroradiol 15: 681–687PubMedGoogle Scholar
  63. 63.
    Nakai A, Goto Y, Fujisawa K et al (1994) Diffuse leukodystrophy with a large-scale mitochondrial DNA deletion. Lancet 343:1397–1398PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2001

Authors and Affiliations

  • N. De Stefano
  • A. Federico

There are no affiliations available

Personalised recommendations